Form 4: Axogen Director Exercises Options, Sells Shares

Axogen Director Amy McBride Wendell exercised stock options and subsequently sold a portion of the acquired common stock on December 16, 2025, under a Rule 10b5-1 plan.

Summary

• Director Amy McBride Wendell of Axogen, Inc. [AXGN] reported transactions on December 16, 2025.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan.
• Wendell exercised stock options to acquire a total of 43,684 shares of common stock.
• These options were exercised at prices of $8.95 (5,000 shares), $6.30 (20,436 shares), and $7.04 (18,248 shares).
• Concurrently, Wendell sold a total of 43,684 shares of common stock at a weighted average price of $29.312 per share.
• The sales occurred in multiple transactions at prices ranging from $28.99 to $29.63 per share.
• Following these transactions, Wendell's direct beneficial ownership of common stock is 93,826 shares.

Sentiment

Score: 6

Explanation: The filing reports a director's exercise of vested stock options and a subsequent sale of the acquired shares under a Rule 10b5-1 plan. This indicates planned portfolio management and the realization of value from long-held options, which is generally neutral. The significant difference between the exercise price and sale price is positive for the director.

Positives

• Director Amy McBride Wendell realized significant value by selling shares at a weighted average price of $29.312, substantially higher than the option exercise prices ($8.95, $6.30, $7.04).
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating planned portfolio management rather than a reaction to immediate news.

Negatives

• A director sold a substantial number of shares (43,684), which could be interpreted as a reduction in direct exposure to the company's stock, although it was part of an option exercise.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Amy McBride Wendell, a related party, exercised stock options and sold common stock of Axogen, Inc. on December 16, 2025.

Stakeholder Impact

• Shareholders may view the director's sale as a signal, though mitigated by the pre-arranged Rule 10b5-1 plan and the context of option exercise.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction involving the exercise of vested stock options and the subsequent sale of shares. While it represents a director reducing their direct shareholding, the execution under a Rule 10b5-1 plan suggests a pre-determined financial management strategy rather than a reaction to new material information. The transaction itself does not provide new fundamental insights into the company's operational performance or future prospects that would warrant a change in investment recommendation. Investors should consider this as a neutral event in the context of a broader investment thesis for Axogen, Inc.

Keywords

Axogen, AXGN, Form 4, insider trading, stock options, director, share sale, Rule 10b5-1